

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 September 2024 (06.09.2024)



(10) International Publication Number
WO 2024/182693 A1

(51) International Patent Classification:

C07D 403/14 (2006.01) A61K 31/497 (2006.01)
C07D 403/12 (2006.01) A61K 31/4725 (2006.01)
C07D 471/04 (2006.01) A61K 31/337 (2006.01)
A61K 31/501 (2006.01) A61P 35/00 (2006.01)
A61K 31/4439 (2006.01) A61P 37/02 (2006.01)
A61K 31/4985 (2006.01)

(21) International Application Number:

PCT/US2024/018053

(22) International Filing Date:

01 March 2024 (01.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/488,117 02 March 2023 (02.03.2023) US

(71) Applicant: **VIVIDION THERAPEUTICS, INC.**
[US/US]; 5820 Nancy Ridge Drive, San Diego, CA 92121 (US).

(72) Inventors: **WU, Qingfeng**; 5820 Nancy Ridge Drive, San Diego, CA 92121 (US). **COOK, Brian**; 5820 Nancy Ridge Drive, San Diego, CA 92121 (US). **WALLACE, Michael**; 5820 Nancy Ridge Drive, San Diego, CA 92121 (US). **POLLACK, Jonathan**; 5820 Nancy Ridge Drive, San Diego, CA 92121 (US). **SNEAD, Aaron**; 5820 Nancy Ridge Drive, San Diego, CA 92121 (US). **LEE, Bryan**; 5820 Nancy Ridge Drive, San Diego, CA 92121 (US). **MALMSTROM, Robert**; 5820 Nancy Ridge Drive, San Diego, CA 92121 (US). **HAMMERSLEY, Gabriel**; 5820 Nancy Ridge Drive, San Diego, CA 92121 (US). **UR-BANO, Mariangela**; 5820 Nancy Ridge Drive, San Diego, CA 92121 (US). **GREEN, Jason**; 5820 Nancy Ridge Drive, San Diego, CA 92121 (US). **ALABI, Philip**; 5820 Nancy Ridge Drive, San Diego, CA 92121 (US).

(74) Agent: **DILMORE, James**; One Bayer Drive, Indianola, PA 15051 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: 2-AZASPIRO[3.3]HEPTANE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER



(A-1)

(57) Abstract: The present invention relates to 2-azaspiro[3.3]heptane derivatives of formula (A-1) as STAT3 inhibitors (signal transducer and activator of a transcription) for the treatment of cancer and immunological diseases.

WO 2024/182693 A1